TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02060617

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Education
Description: All subjects will receive education that back pain is common but rarely harmful in nature, that pain does not necessarily mean that there is structural damage to their back, and that they should try to remain as active as they are able within the limits of their pain. In addition, individualized education regarding posture, body mechanics, sleeping positions, or other concerns of the patient will be provided on a pragmatic basis as deemed appropriate by the treating clinician.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: All subjects will receive education that back pain is common but rarely harmful in nature, that pain does not necessarily mean that there is structural damage to their back, and that they should try to remain as active as they are able within the limits of their pain. In addition, individualized education regarding posture, body mechanics, sleeping positions, or other concerns of the patient will be provided on a pragmatic basis as deemed appropriate by the treating clinician.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual therapy of the thoracolumbosacral spine and hips
Description: Thrust and/or non-thrust manipulation and soft tissue mobilization as determined by mobility impairments identified on clinical examination.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Motor control exercises
Description: Motor control exercises as determined by motor control impairments identified on clinical examination.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-Based Classification intervention
Description: Lumbopelvic manipulation and range of motion exercise, spinal stabilization exercises, direction specific exercises, and/or traction will be applied as determined by the Treatment-Based Classification (TBC) Algorithm.
Study: NCT02714673

Intervention type: DRUG
Intervention: anticoagulation
Description: anticoagulation refers to any long term effective anticoagulation including antivitamin K, direct oral anticoagulants. Aspirin, clopidogrel are not included
Study: NCT03008746

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water used for oral wash

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water used for oral wash
Study: NCT01575262

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-cash incentives
Description: Participants used their PAL card to self-monitor physical activity levels (intrinsic motivation) and minutes of physical activity were converted to points (1 minute of PA = 1 point; capped at 30 points per day) over the 12-week intervention period. Points were redeemed for rewards (extrinsic motivation) at week 6 and week 12.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-monitoring physical activity levels
Description: For those in the 'No Incentive' arm, participants used their PAL card to self-monitor their physical activity levels but did not collect points or earn rewards.
Study: NCT03776617

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: scalp block
Description: Scalp block will be performed five minutes before head pinning for elective craniotomy by blocking supraorbital, auriculotemporal, occipital and postauricular branches of the greater auricular nerves.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: scalp block
Description: Scalp block will be performed five minutes before head pinning for elective craniotomy by blocking supraorbital, auriculotemporal, occipital and postauricular branches of the greater auricular nerves.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: scalp block
Description: Scalp block will be performed five minutes before head pinning for elective craniotomy by blocking supraorbital, auriculotemporal, occipital and postauricular branches of the greater auricular nerves.
Study: NCT06390865

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Given PO
Study: NCT00595335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Subjects will receive 2 infusions of rituximab (1000 mg IV), two weeks apart.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV.
Study: NCT03008746

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water used for oral wash

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sputum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sputum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sputum
Study: NCT04076709

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: goal directed anaesthesia
Description: Deep neuromuscular blockade (PTC 1-2) Nociception level index (NOL) target 10-25
Study: NCT03336606

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEDI0562
Description: Surgical resection of tumor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEDI0562
Description: Surgical resection of tumor
Study: NCT03008746

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral wash

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral wash

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral wash
Study: NCT02148458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: Mediterranean diet for 8 weeks, followed by 8 weeks of Mediterranean diet with intermittent fasting (i.e. 2 non-consecutive days of fasting per week)
Study: NCT02328300

Intervention type: DRUG
Intervention: FLT PET/MR
Description: Each participant will be injected with FLT, a common PET radiotracer for brain tumors and lesions, and then will complete one (1) PET/MR scan.
Study: NCT00268788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous immunoglobulin
Description: Individually dosed, given twice a week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous immunoglobulin
Description: Individual dose and frequency
Study: NCT03570697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Participants will receive evolocumab (AMG 145) subcutaneous monthly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo subcutaneous monthly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin therapy
Description: high-intensity statin treatment with atorvastatin ≥ 40 mg daily or equivalent as background therapy~Investigators will up-titrate statin therapy to the maximally tolerated dose, in accordance with local guidelines, prior to randomization.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Statin therapy
Description: high-intensity statin treatment with atorvastatin ≥ 40 mg daily or equivalent as background therapy~Investigators will up-titrate statin therapy to the maximally tolerated dose, in accordance with local guidelines, prior to randomization.
Study: NCT03141437

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive standard of care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive educational materials
Study: NCT00595335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Subjects will receive methylprednisolone 100 mg IV as premedication to the rituximab infusion.
Study: NCT03307980

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06838435 (formerly SPK-9001)
Description: Gene Therapy: A novel, bioengineered adeno-associated viral vector carrying human factor IX variant
Study: NCT00807209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose SKY0402
Description: Bupivacaine, 15 mg/mL via epidural PLUS single total administration of 75mg SKY0402 (25 mg to each of three segments) in 4 mL volume each for a total of 12 mL via nerve block (intercostal)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose SKY0402
Description: Bupivacaine, 15 mg/mL via epidural PLUS single total administration of 150 mg (50 mg to each of three segments) in 4 mL volume each for a total of 12 mL via nerve block (intercostal)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Bupivacaine, 15 mg/mL per epidural PLUS administration of 4 mL Placebo to each of three nerves for a total of 12 mL (intercostal)
Study: NCT05358730

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Exercise
Description: Glenohumeral exercises, scapulothoracic exercises, stretching exercises and mobilization exercises were performed under the supervision of a physiotherapist two days per week for six weeks at the clinical setting (Celik and Kaya Mutlu, 2016).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Exercise
Description: Glenohumeral exercises, scapulothoracic exercises, stretching exercises and mobilization exercises were performed under the supervision of a physiotherapist two days per week for six weeks at the clinical setting (Celik and Kaya Mutlu, 2016).
Study: NCT03141437

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive educational materials

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Use decision-making website
Study: NCT05358730

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft Tissue Mobilization (IASTM)
Description: IASTM treatment was applied to the posterior-anterior-middle deltoid, latissimus dorsi, teres major, teres minor, supraspinatus and infraspinatus muscle fibers, superficial and deep fascia. IASTM was applied in parallel and vertical direction to the muscle fibers treated with the instrument at a 45° angle, each technique (SWEEP, BRUSH (straight short steps) techniques) for 20 seconds (Ikeda, Otsuka, Kawanishi, and Kawakami, 2019). It was performed two days per week for six weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Exercise
Description: Hme exercise program consisted of glenohumeral exercises, scapulothoracic exercises, stretching exercises and mobilization exercises.~It was asked to perform two days per week for six weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise
Description: Hme exercise program consisted of glenohumeral exercises, scapulothoracic exercises, stretching exercises and mobilization exercises.~It was asked to perform two days per week for six weeks.
Study: NCT02148458

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: control group eating their usual Western diet for 8 weeks, followed by 8 weeks of usual diet with intermittent fasting (i.e. 2 non-consecutive days of fasting per week).
Study: NCT00659919

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00807209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl via PCA
Description: Fentanyl via PCA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl via PCA
Description: Fentanyl via PCA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl via PCA
Description: Fentanyl via PCA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine via epidural
Description: Bupivacaine via epidural

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine via epidural
Description: Bupivacaine via epidural

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine via epidural
Description: Bupivacaine via epidural
Study: NCT03574337

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: No additional information

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neostigmine/glycopyrolate
Description: No additional information
Study: NCT02447887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: The prescribed administration of ixazomib doses in this study is 1.5-4.0 mg ixazomib weekly for 3 out of 4 weeks in each cycle (1 cycle=28 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated IFN-alpha 2b
Description: Weekly injection
Study: NCT04118946

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: platelet enriched plasma
Description: PRP is prepared via a two-step centrifugation preparation of a blood sample, which is cured with an anticoagulant. Then either with be applied through urethral catheter in one arm or via submucos injection in anther one.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: platelet enriched plasma
Description: PRP is prepared via a two-step centrifugation preparation of a blood sample, which is cured with an anticoagulant. Then either with be applied through urethral catheter in one arm or via submucos injection in anther one.
Study: NCT03141437

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03792737

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spiral PDS Plus
Description: The Spiral PDS Plus is an antibacterial monofilament, synthetic absorbable device. It contains triclosan, a broad spectrum antibacterial agent. The device consists of barbed suture material, armed with a surgical needle on one end and a fixation loop at the opposite end. The device is designed to anchor with a closed loop at one end and a unidirectional barbed section on the other end. Spiral PDS Plus barbs are oriented in one direction to allow tissue approximation without the need to tie surgical knots.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spiral MONOCRYL Plus
Description: The Spiral MONOCRYL Plus is an antibacterial monofilament, synthetic absorbable device. It contains triclosan, a broad spectrum antibacterial agent. The device consists of barbed suture material, armed with a surgical needle on one end and a fixation loop at the opposite end. The device is designed to anchor with a closed loop at one end and a unidirectional barbed section on the other end. Spiral MONOCRYL Plus barbs are oriented in one direction to allow tissue approximation without the need to tie surgical knots.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PDS Plus
Description: PDS Plus is a non-barbed antibacterial monofilament, synthetic absorbable suture. The suture contains triclosan, a broad spectrum antibacterial agent.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDS Plus
Description: PDS Plus is a non-barbed antibacterial monofilament, synthetic absorbable suture. The suture contains triclosan, a broad spectrum antibacterial agent.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MONOCRYL Plus
Description: MONOCRYL Plus is a non-barbed antibacterial monofilament, synthetic absorbable suture. The suture contains triclosan, a broad spectrum antibacterial agent.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MONOCRYL Plus
Description: MONOCRYL Plus is a non-barbed antibacterial monofilament, synthetic absorbable suture. The suture contains triclosan, a broad spectrum antibacterial agent.
Study: NCT02662192

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise + health education+ auditory rehabilitation
Description: comparison of 3/4 of an hour balance, resistance and strength training, 1 hour health education, 1 hour auditory rehabilitation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: auditory rehabilitation alone
Description: 10 weeks of one hour per week of group auditory rehabilitation
Study: NCT03792737

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VICRYL Plus
Description: VICRYL Plus antibacterial suture is a non-barbed synthetic absorbable sterile, surgical suture. The suture contains triclosan, a broad spectrum antibacterial agent.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VICRYL Plus
Description: VICRYL Plus antibacterial suture is a non-barbed synthetic absorbable sterile, surgical suture. The suture contains triclosan, a broad spectrum antibacterial agent.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VICRYL Plus
Description: VICRYL Plus antibacterial suture is a non-barbed synthetic absorbable sterile, surgical suture. The suture contains triclosan, a broad spectrum antibacterial agent.
Study: NCT00085839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva (Trademark) (erlotinib HCl, OSI-774)
Description: Erlotinib tablets administered orally, 150 mg/day (starting dose) or 100 mg/day (reduced dose), continuous therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination carboplatin and paclitaxel
Description: Paclitaxel 200 mg/m\^2 IV infusion over 3 hours and carboplatin AUC 6 mg/mL x min IV over 15 - 30 minutes, both given on Day 1 every 21 days for 4 cycles
Study: NCT04598425

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia (CBTi)
Description: Patients will undergo a 7 sessions course in cognitive behavioral therapy for insomnia.
Study: NCT01427478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFATINIB
Description: AFATINIBat the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of AFATINIB
Description: placebo of Afatinib at the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months
Study: NCT00683787

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: Given IV once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vandetanib
Description: Oral vandetanib once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vandetanib
Description: Oral vandetanib once daily
Study: NCT03651908

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Flap Surgery
Description: After administering local anaesthetic a full thickness flap will be raised and reflected to expose the intrabony defects.The intrabony defects would then the debrided and grafts secured in position.Later the flap would be sutured back.~After administering local anaesthetic a full thickness flap will be raised and reflected to expose the intrabony defects.The intrabony defects would then the debrided and grafts secured in position.Later the flap would be sutured back.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Flap Surgery
Description: After administering local anaesthetic a full thickness flap will be raised and reflected to expose the intrabony defects.The intrabony defects would then the debrided and grafts secured in position.Later the flap would be sutured back.~After administering local anaesthetic a full thickness flap will be raised and reflected to expose the intrabony defects.The intrabony defects would then the debrided and grafts secured in position.Later the flap would be sutured back.
Study: NCT01411488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fecal management system
Description: rectal tubes/fecal management systems: we compared products to determine if there is a difference in the incidence of anal erosions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fecal management system
Description: rectal tubes/fecal management systems: we compared products to determine if there is a difference in the incidence of anal erosions
Study: NCT01110044

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 251154 vaccine
Description: Intramuscular, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa™
Description: Intramuscular, four doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa™
Description: Intramuscular, four doses
Study: NCT00659919

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Study: NCT04045249

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Home based food
Description: Home based food is compare able to RUTF

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Home based food
Description: Home based food is compare able to RUTF
Study: NCT00757562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desloratadine
Description: desloratadine syrup: 1.25 mg (2.5 mL) for subjects \>=2 to \<6 years, 2.5 mg (5 mL) for subjects \>=6 to \<12 years, orally once daily in the morning for 36 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo syrup: 2.5 mL for subjects \>=2 to \<6 years, 5 mL for subjects \>=6 to \<12 years, orally once daily in the morning for 36 days.
Study: NCT02027298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: by SC injection of 125 mg weekly for 6 months
Study: NCT02618850

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PET/CT
Description: PET/CT scan at baseline and 10-14 days after day 1 of first cycle chemotherapy

Intervention type: DRUG
Group type: OTHER
Intervention: first-line chemotherapy
Description: as prescribed by oncologist
Study: NCT05029596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline Group
Description: A 10cc NS flush will be administered intravenously through the peripherally inserted central line catheter after administration of medication, blood products, and blood draws. In addition the peripherally inserted central line catheter will be flushed intravenously with 10cc Normal Saline every 24 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin Group
Description: All lumens of PICC line will be flushed w/ Heparin Flush every 8 hours. PICC line will be flushed with 10cc Normal Saline followed by 3cc Heparin Flush after administration of medication, blood products, or blood draws.
Study: NCT01110044

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synflorix™
Description: Intramuscular, four doses
Study: NCT02026622

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: psychometric tests
Description: NEO-PI, MADRS, MINI depression, MMSE, STAI-E, ERD, Anhedonia
Study: NCT02280161

Intervention type: OTHER
Intervention: cytology specimen collection procedure
Description: Correlative studies